贝前列素联合匹伐他汀治疗慢性阻塞性肺疾病相关肺动脉高压的效果  

Effect of Beraprost combined with Pitavastatin in the treatment of chronic obstructive pulmonary disease-related pulmonary hypertension

作　　者：李丽华[1] 陈媛慧 李莹 LI Lihua;CHEN Yuanhui;LI Ying(Department of Geriatrics,the First Hospital of Nanchang,Jiangxi Province,Nanchang330008,China;Department of Image Center,the First Hospital of Nanchang,Jiangxi Province,Nanchang330008,China)

机构地区：[1]南昌市第一医院老年医学科,江西南昌330008 [2]南昌市第一医院影像中心,江西南昌330008

出　　处：《中国当代医药》2022年第2期45-47,51,共4页China Modern Medicine

基　　金：江西省卫生厅科技计划项目(20167021)。

摘　　要：目的研究贝前列素与匹伐他汀联合治疗慢性阻塞性肺疾病(COPD)相关肺动脉高压的效果。方法选取2019年12月至2020年12月南昌市第一医院收治的100例COPD相关肺动脉高压患者作为研究对象,采用随机抽签分组原则将其分为观察组和对照组,每组50例。观察组采用贝前列素联合匹伐他汀治疗方式,对照组采用贝前列素治疗方式。比较两组患者的总有效率、肺功能指标、炎症因子指标。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组第1秒用力呼出气体体积(FEV1)、第1秒用力呼出气体体积/用力肺活量(FEV1/FVC)、FEV1占预计值的百分比(FEV1%)均高于对照组,差异有统计学意义(P<0.05)。观察组COPD相关肺动脉高压患者血液中性粒细胞、白细胞介素8(IL-8)及肿瘤坏死因子-α(TNF-α)指标均低于对照组,差异有统计学意义(P<0.05)。结论和贝前列素单药治疗比较,贝前列素与匹伐他汀联合治疗COPD相关肺动脉高压的效果较好,能够使患者肺功能指标得到改善。Objective To study the effect of Beraprost and Pitavastatin in the treatment of chronic obstructive pulmonary disease(COPD)-related pulmonary hypertension.Methods A total of 100 COPD-related pulmonary hypertension patients admitted to the First Hospital of Nanchang from December 2019 to December 2020 were selected as the research subjects.They were divided into an observation group and a control group according to the principle of random drawing,with 50 cases in each group.Patients in the observation group were treated with Beraprost combined with Pitavastatin,and patients in the control group were treated with Beraprost.The total effectiveness rate,lung function indexes,and inflammatory factors of the two groups of patients were compared.Results The total effectiveness rate of treatment in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).The forced expiratory volume in the first second(FEV1),the forced expiratory volume in the first second/forced vital capacity(FEV1/FVC)and percentage of predicted value of the FEV1(FEV1%)of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).The indexes of blood neutrophils,interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in patients with COPD-related pulmonary hypertension in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion Compared with Beraprost monotherapy,the combination of Beraprost and Pitavastatin has a better effect in the treatment of COPD-related pulmonary hypertension,which can improve the patients′lung function indicators.

关 键 词：贝前列素 匹伐他汀 肺动脉高压 治疗 效果 

分 类 号：R563.9[医药卫生—呼吸系统]